Tucatinib plus trastuzumab emtansine may benefit patients with advanced or metastatic HER2-positive breast cancer
A combination of two HER2-targeted drugs, tucatinib (Tukysa) and trastuzumab emtansine (Kadcyla, T-DM1), extended progression-free survival among patients with unresectable locally advanced or metastatic HER2-positive breast ...